These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 10656997)
1. Urocortin is the principal ligand for the corticotrophin-releasing factor binding protein in the ovine brain with no evidence for a sauvagine-like peptide. Baigent SM; Lowry PJ J Mol Endocrinol; 2000 Feb; 24(1):53-63. PubMed ID: 10656997 [TBL] [Abstract][Full Text] [Related]
2. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Lewis K; Li C; Perrin MH; Blount A; Kunitake K; Donaldson C; Vaughan J; Reyes TM; Gulyas J; Fischer W; Bilezikjian L; Rivier J; Sawchenko PE; Vale WW Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7570-5. PubMed ID: 11416224 [TBL] [Abstract][Full Text] [Related]
3. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Vaughan J; Donaldson C; Bittencourt J; Perrin MH; Lewis K; Sutton S; Chan R; Turnbull AV; Lovejoy D; Rivier C Nature; 1995 Nov; 378(6554):287-92. PubMed ID: 7477349 [TBL] [Abstract][Full Text] [Related]
4. Characterization of a sheep brain corticotropin releasing factor binding protein. Behan DP; Cepoi D; Fischer WH; Park M; Sutton S; Lowry PJ; Vale WW Brain Res; 1996 Feb; 709(2):265-74. PubMed ID: 8833763 [TBL] [Abstract][Full Text] [Related]
5. Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity. Dautzenberg FM; Huber G; Higelin J; Py-Lang G; Kilpatrick GJ Neuropharmacology; 2000 Jun; 39(8):1368-76. PubMed ID: 10818253 [TBL] [Abstract][Full Text] [Related]
6. Urocortin interaction with corticotropin-releasing factor (CRF) binding protein (CRF-BP): a novel mechanism for elevating "free' CRF levels in human brain. Behan DP; Khongsaly O; Ling N; De Souza EB Brain Res; 1996 Jul; 725(2):263-7. PubMed ID: 8836534 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterisation of the recombinant human CRF binding protein using a simple assay. Ardati A; Gottowik J; Henriot S; Clerc RG; Kilpatrick GJ J Neurosci Methods; 1998 Mar; 80(1):99-105. PubMed ID: 9606055 [TBL] [Abstract][Full Text] [Related]
8. Cloning and characterization of human urocortin. Donaldson CJ; Sutton SW; Perrin MH; Corrigan AZ; Lewis KA; Rivier JE; Vaughan JM; Vale WW Endocrinology; 1996 May; 137(5):2167-70. PubMed ID: 8612563 [TBL] [Abstract][Full Text] [Related]
10. Corticotropin-releasing factor-binding protein (CRF-BP) inhibits CRF- and urotensin-I-mediated activation of CRF receptor-1 and -2 in common carp. Manuel R; Metz JR; Flik G; Vale WW; Huising MO Gen Comp Endocrinol; 2014 Jun; 202():69-75. PubMed ID: 24769042 [TBL] [Abstract][Full Text] [Related]
11. Ligand requirements of the human corticotropin-releasing factor-binding protein. Sutton SW; Behan DP; Lahrichi SL; Kaiser R; Corrigan A; Lowry P; Potter E; Perrin MH; Rivier J; Vale WW Endocrinology; 1995 Mar; 136(3):1097-102. PubMed ID: 7867564 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of recombinant rat corticotropin releasing factor binding protein using different sauvagine analogs. Jahn O; Eckart K; Sydow S; Hofmann BA; Spiess J Peptides; 2001 Jan; 22(1):47-56. PubMed ID: 11179597 [TBL] [Abstract][Full Text] [Related]
13. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Liaw CW; Grigoriadis DE; Lorang MT; De Souza EB; Maki RA Mol Endocrinol; 1997 Dec; 11(13):2048-53. PubMed ID: 9415408 [TBL] [Abstract][Full Text] [Related]
14. Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin. Gottowik J; Goetschy V; Henriot S; Kitas E; Fluhman B; Clerc RG; Moreau JL; Monsma FJ; Kilpatrick GJ Neuropharmacology; 1997 Oct; 36(10):1439-46. PubMed ID: 9423932 [TBL] [Abstract][Full Text] [Related]
15. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile. Dautzenberg FM; Kilpatrick GJ; Wille S; Hauger RL J Neurochem; 1999 Aug; 73(2):821-9. PubMed ID: 10428081 [TBL] [Abstract][Full Text] [Related]
16. An artificial peptide with corticotropin-releasing factor receptor-2 (CRF-R2) selective properties: the role of primary structure in the induction of signal transduction pathways. Tellam DJ; Smart D; Qian X; Lovejoy DA J Pept Res; 2002 Oct; 60(4):215-22. PubMed ID: 12366528 [TBL] [Abstract][Full Text] [Related]
17. Urocortins of the South African clawed frog, Xenopus laevis: conservation of structure and function in tetrapod evolution. Boorse GC; Crespi EJ; Dautzenberg FM; Denver RJ Endocrinology; 2005 Nov; 146(11):4851-60. PubMed ID: 16037378 [TBL] [Abstract][Full Text] [Related]
18. A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity. Perrin MH; DiGruccio MR; Koerber SC; Rivier JE; Kunitake KS; Bain DL; Fischer WH; Vale WW J Biol Chem; 2003 May; 278(18):15595-600. PubMed ID: 12611895 [TBL] [Abstract][Full Text] [Related]
19. The suppression effects of feeding and mechanisms in CRF system of animals. Qi J; Zhang X; Li Y; Xu S; Wang M; Chen H; Tang N; Wang S; Wang B; Chen D; Zhou B; Li Z Gene; 2020 Apr; 733():144363. PubMed ID: 31935510 [TBL] [Abstract][Full Text] [Related]
20. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Behan DP; De Souza EB; Lowry PJ; Potter E; Sawchenko P; Vale WW Front Neuroendocrinol; 1995 Oct; 16(4):362-82. PubMed ID: 8557170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]